Find Capmatinib Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1865733-40-9, Nvp-inc280-aaa, Capmatinib hydrochloride [usan], C2a374o70x, Capmatinib (dihydrochloride hydrate), Tabrecta
Molecular Formula
C23H21Cl2FN6O2
Molecular Weight
503.4  g/mol
InChI Key
COWBUPJEEDYWKD-UHFFFAOYSA-N
FDA UNII
C2A374O70X

Capmatinib Hydrochloride
Capmatinib Hydrochloride is the hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
1 2D Structure

Capmatinib Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;hydrate;dihydrochloride
2.1.2 InChI
InChI=1S/C23H17FN6O.2ClH.H2O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20;;;/h2-9,11-13H,10H2,1H3,(H,25,31);2*1H;1H2
2.1.3 InChI Key
COWBUPJEEDYWKD-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F.O.Cl.Cl
2.2 Other Identifiers
2.2.1 UNII
C2A374O70X
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzoic Acid

2. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)-(1,2,4)triazin-2-yl)benzamide

3. 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- B)(1,2,4)triazin-2-yl)benzamide Dihydrochloride Monohydrate

4. 2-fluoro-n-methyl-4-(7-(quinolin-6-yl-methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

5. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

6. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide Dihydrochloride

7. Capmatinib

8. Capmatinib Dihydrochloride

9. Capmatinib Dihydrochloride Monohydrate

10. Capmatinib Hydrochloride Anhydrous

11. Capmatinib Metabolite M13

12. Capmatinib Metabolite M18

13. Cmc-583

14. Cmc583

15. Cnj-294

16. Cnj294

17. Inc-280

18. Inc280

19. Incb-28060

20. Incb-28060 Free Base

21. Incb28060

22. Nvp-inc280

23. Nvp-inc280-nx

24. Tabrecta

2.3.2 Depositor-Supplied Synonyms

1. 1865733-40-9

2. Nvp-inc280-aaa

3. Capmatinib Hydrochloride [usan]

4. C2a374o70x

5. Capmatinib (dihydrochloride Hydrate)

6. Tabrecta

7. Capmatinib Dihydrochloride Monohydrate

8. Capmatinib Hydrochloride (usan)

9. Capmatinib Hydrochloride Hydrate (jan)

10. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide Dihydrochloride Hydrate

11. Capmatinib Hydrochloride Hydrate [jan]

12. Tabrecta (tn)

13. Capmatinib 2hcl.h2o

14. Capmatinib 2hcl Hydrate

15. Inc-280 Hydrochloride

16. Incb28060 Hydrochloride

17. Unii-c2a374o70x

18. Capmatinib Hydrochloride Hydrate

19. Chembl3989937

20. Dtxsid401027869

21. Hy-13404c

22. Capmatinib Hydrochloride [who-dd]

23. Capmatinib Hydrochloride Monohydrate

24. Cs-0198834

25. Capmatinib Hydrochloride [orange Book]

26. D10891

27. Q27895918

28. 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- B)(1,2,4)triazin-2-yl)benzamide Dihydrochloride Monohydrate

29. Benzamide, 2-fluoro-n-methyl-4-(7-(6-quinolinylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)-, Hydrochloride, Hydrate (1:2:1)

2.4 Create Date
2016-11-15
3 Chemical and Physical Properties
Molecular Weight 503.4 g/mol
Molecular Formula C23H21Cl2FN6O2
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count7
Rotatable Bond Count4
Exact Mass502.1087075 g/mol
Monoisotopic Mass502.1087075 g/mol
Topological Polar Surface Area86.1 Ų
Heavy Atom Count34
Formal Charge0
Complexity637
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count4
4 Drug and Medication Information
4.1 Drug Indication

Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.


5 Pharmacology and Biochemistry
5.1 ATC Code

L01EX17


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty